Precigen 10% Owner Randal Kirk Sold About $45.1M After PAPZIMEOS Won FDA Approval

Randal J. Kirk, a 10% owner of Precigen, sold about $45.1 million of stock across a September-to-December 2025 window. The context is what makes the tape interesting. In August 2025, Precigen announced full FDA approval of PAPZIMEOS for adults with recurrent respiratory papillomatosis, turning the company into a commercial-stage biotech with its first approved product in the U.S. The company then highlighted long-term follow-up results on the same platform. That means Kirk was selling after a major de-risking event, not ahead of one.

The Selling Window

Date	Shares Sold	Estimated Value	Context
2025-09-18 to 2025-09-30	6.81M	~$24.8M	Large post-approval monetization wave
2025-11-19 to 2025-11-21	2.97M	~$12.3M	Second major sale cluster
2025-12-22	1.90M	~$7.9M	Final highlighted 2025 sale day
Total highlighted sales	11.68M+	~$45.1M	While still retaining a multi-million-share stake

Why This Matters

Precigen's own website now centers the PAPZIMEOS approval as a defining milestone and points investors to the FDA announcement and long-term follow-up materials. That is a very different setup from a speculative pre-approval biotech story. Kirk's sales came after the company crossed a major regulatory threshold and started presenting itself as a commercial-stage medicine company.

That shifts the frame. Investors should not read this as a binary “insider knows bad news” pattern. It looks more like a large holder monetizing after a dramatic reduction in regulatory uncertainty.

Why Retail Investors Should Still Pay Attention

Biotech insiders and large holders often sell after clinical or regulatory wins because liquidity finally appears. But the size here is still material enough to matter. Selling $45.1 million in a few months is not token diversification. For investors in event-driven biotech names such as CRISPR Therapeutics, Intellia, Editas, or diagnostics-growth names like Guardant Health, the lesson is the same: post-catalyst insider behavior helps separate “milestone monetization” from ongoing insider accumulation.

Key Facts

Metric	Value
Insider	Randal J. Kirk
Company	Precigen (PGEN)
Highlighted sale window	Sep. 18, 2025 to Dec. 22, 2025
Estimated value sold	~$45.1M
Major backdrop event	FDA approval of PAPZIMEOS in August 2025
Platform backdrop	Company later highlighted long-term follow-up results

What To Watch

• Further 10% owner sales: Another wave after the approval cycle would change the tone.
• Commercial uptake: The approval matters less if PGEN cannot translate it into durable commercialization.
• Biotech context: Compare insider behavior in PGEN with peers like CRSP, NTLA, EDIT, and GH.
• Signal hygiene: For framework, read our Form 4 explainer, our combined 13F/Form 4 guide, and our comparison guide.